Company Description
Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases.
Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.
The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.
| Country | Switzerland |
| Founded | 2024 |
| IPO Date | Nov 13, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Luca Santarelli |
Contact Details
Address: Aeschenplatz 6 Basel, 4052 Switzerland | |
| Phone | 41 61 551 75 75 |
| Website | windwardbio.com |
Stock Details
| Ticker Symbol | WWB |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 2145089 |
| ISIN Number | CH1623933509 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Luca Santarelli | Chief Executive Officer and Chair of the Board of Directors |
| Claudia DāAugusta | Chief Financial Officer |
| Omar Khwaja | Chief Medical Officer |
| Kevin Harris | Chief Operating Officer |
| Scott Applebaum | Chief Legal and Corporate Development Officer |
| David P. Bonita | Director |
| Timothy Anderson | Director |
| Naveed I. Siddiqi | Director |
| Iqbal Mufti | Director |
| Otello Stampacchia | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 16, 2026 | 6-K | Report of foreign issuer |
| Nov 16, 2026 | 424B4 | Prospectus |
| Nov 16, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 13, 2026 | FWP | Free Writing Prospectus |
| Nov 12, 2026 | EFFECT | Notice of Effectiveness |
| Nov 12, 2026 | CERT | Certification by an exchange approving securities for listing |
| Nov 9, 2026 | 8-A12B | Registration of securities |
| Nov 9, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Oct 30, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |